Come up with a name for your new list and we'll add to it:
ProRetina raised a round of funding on January 26, 2013. Investors include
Caixa Capital Risc.
ProRetina develops a drug for the treatment of retinitis pigmentosa, a genetic disease that causes a gradual degeneration of the retina and eventually blindness for which no current effective treatmen…